Meanwhile, with the development of immunotherapy, the treatment effect via intravenous infusion is likely, due to the adenovirus-mediated delivery of the WT p53-induced p53-specific immune response, via DCs (Dendritic cells) and sensitized SCLC (Small Cell Lung Cancer), subsequent to chemotherapy. The gene discussed is TP53; the disease is small cell lung carcinoma.